General Counsel John Moore sells 70,922 shares for $1,996,574.40, reducing stake from 74,174 to 3,252 shares.
John R Moore, General Counsel at Edgewise Therapeutics (EWTX), executed 2 separate sales totaling 70,922 shares for $1,996,574.40 on 2024-09-20 and 2024-09-23 at blended average price of $28.15, reducing his holdings by 95.6%. The company is unprofitable with full-year net income of $-31,497,000.00. At current price of $25.92, the stock is -12.1% from its 52-week high of $29.50, though it has risen 34.1% over the prior 30 days and 48.3% over 90 days. Moore's cross-ticker track record across 3 prior open-market sells shows an average 90-day return of +3.5% and a well-timed rate of 33.33%, indicating his prior sales have been poorly timed overall (stock rose after). His same-ticker history at EWTX shows 1 of 3 prior sells were well-timed at the 90-day mark, with mixed outcomes ranging from -14.2% to +6.2% over 90 days. The near-complete exit—retaining only 3,252 shares post-transaction—combined with the company's unprofitable status and the stock's recent strength creates a material disclosure event, though the executive's prior sales have not demonstrated reliable timing precision.